Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

Indication: Non-Small Cell Lung Cancer (NSCLC)

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Advanced Non-Squamous

Line of Therapy: 2nd Line

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: Mirati Therapeutics, Inc

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.